Tectonic Therapeutic Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Tectonic Therapeutic Inc.
- Former names
- AvroBio, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- New York
- Headquarters city
- Watertown
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- TECX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001681087
- EIN
- 81-0710585
Board of directors
-
Alise Reicin · Director · Chief Executive OfficerSince 2024
-
Annalisa Jenkins · DirectorSince 2023
-
Bruce Booth · DirectorSince 2023
-
Christopher Paige · DirectorSince 2023
-
Francois Nader · DirectorSince 2026
-
Gail M. Farfel · DirectorSince 2023
-
Geoffrey Mackay · Director · President & CEOSince 2023
- Since 2023
-
Jessica Caroline Chutter · DirectorSince 2026
-
Philip J. Vickers · DirectorSince 2023
-
Phillip B. Donenberg · DirectorSince 2023
-
Praveen P. Tipirneni · DirectorSince 2024
-
Stefan Vitorovic · DirectorSince 2024
- Since 2024
-
Timothy A. Springer · DirectorSince 2024
Chief executives
Alise Reicin
· Chief Executive Officer
Dates unknown
Geoffrey Mackay
· President & CEO
Dates unknown
Director election results
Annual meeting of June 8, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
79.5%
-
96.6%
Board connections
12 of this board's directors also sit on 27 other boards.
- via Philip J. Vickers
- via Terrance Mcguire
- via Ian T. Clark
- via Praveen P. Tipirneni
- via Annalisa Jenkins
- via Timothy A. Springer
- via Ian T. Clark
- via Phillip B. Donenberg
- via Ian T. Clark
- via Ian T. Clark
- via Alise Reicin
- via Terrance Mcguire
- via Terrance Mcguire
- via Bruce Booth
- via Ian T. Clark
- via Annalisa Jenkins
- via Francois Nader
- via Ian T. Clark
- via Jessica Caroline Chutter
- via Gail M. Farfel
- via Alise Reicin
- via Alise Reicin
- via Terrance Mcguire
- via Bruce Booth
- via Annalisa Jenkins
- via Ian T. Clark
- via Phillip B. Donenberg
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $182,410
- 2 purchases by 2 insiders
- Sold, last 12 months
- $638,657
- 10 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 25, 2026 | McNamara Peter Officer (Chief Scientific Officer) | Option exercise | +43 | $14.71 | $633 |
| Aug 25, 2026 | McNamara Peter Officer (Chief Scientific Officer) | Open-market sale | −43 | $36.52 | $1,570 |
| Aug 12, 2026 | McNamara Peter Officer (Chief Scientific Officer) | Option exercise | +43 | $14.71 | $633 |
| Aug 12, 2026 | McNamara Peter Officer (Chief Scientific Officer) | Open-market sale | −43 | $35.00 | $1,505 |
| Jun 30, 2026 | McNamara Peter Officer (Chief Scientific Officer) | Option exercise | +172 | $14.71 | $2,530 |
| Jun 30, 2026 | McNamara Peter Officer (Chief Scientific Officer) | Open-market sale | −172 | $35.00 | $6,020 |
| Jun 20, 2026 | Alise Reicin Director, Officer (Chief Executive Officer) | Shares withheld for tax | −924 | $30.34 | $28,034 |
| May 4, 2026 | Marcella K. Ruddy Officer (Chief Medical Officer) | Open-market sale | −1,065 | $30.00 | $31,950 |
| Apr 1, 2026 | Marcella K. Ruddy Officer (Chief Medical Officer) | Open-market sale | −1,000 | $31.05 | $31,050 |
| Mar 6, 2026 | Marcella K. Ruddy Officer (Chief Medical Officer) | Open-market sale | −10,000 | $30.00 | $300,000 |
| Mar 6, 2026 | McNamara Peter Officer (Chief Scientific Officer) | Option exercise | +2,500 | $2.38 | $5,950 |
| Mar 6, 2026 | McNamara Peter Officer (Chief Scientific Officer) | Option exercise | +215 | $14.71 | $3,163 |
| Mar 6, 2026 | McNamara Peter Officer (Chief Scientific Officer) | Open-market sale | −6,047 | $30.00 | $181,410 |
| Mar 6, 2026 | McNamara Peter Officer (Chief Scientific Officer) | Open-market sale | −215 | $35.00 | $7,525 |
| Mar 4, 2026 | Alise Reicin Director, Officer (Chief Executive Officer) | Grant or award | +76,500 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.